To directly assess whether the observed antitumor effects were attributed to the generation of functional tumor antigen-specific CD8+ T cells, we next performed antibody-mediated depletion of either CD8+ or CD4+ T cells in B16-F10-bearing STINGgt/gt mice receiving the combination therapy. The gene discussed is CD8A; the disease is neoplasm.